B Christensen1,2,3, D Micic4, P R Gibson1, A Yarur5, E Bellaguarda4, P Corsello6, J N Gaetano3, J Kinnucan6, V L Rao3, S Reddy4, S Singh5, J Pekow3, D T Rubin3. 1. Alfred Hospital and Monash University, Melbourne, Australia. 2. Royal Melbourne Hospital, Melbourne, Australia. 3. University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL, USA. 4. Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 5. Division of Gastroenterology and Hepatology, Medical College of Wisconsin, Milwaukee, WI, USA. 6. University of Michigan Health System, Ann Arbor, MI, USA.
Abstract
BACKGROUND: Blocking of lymphocyte trafficking to bile ducts is a potential mechanism to alter the disease course of patients with primary sclerosing cholangitis (PSC). AIM: To describe the effect of the α4 β7 integrin antibody, vedolizumab, on liver biochemistry and disease activity in patients with PSC and inflammatory bowel disease (IBD). METHODS: This is a retrospective multi-centre study of adult patients with a diagnosis of both IBD and PSC. The primary outcome was change in serum alkaline phosphatase level at weeks 14 and 30. Secondary outcomes included changes in other liver biochemistries and in clinical outcomes for the bowel disease. A safety analysis for adverse events was performed. RESULTS: Thirty-four patients (16 Crohn's disease, 18 ulcerative colitis) were included. Nine (26%) had a history of liver transplant. Median follow-up on vedolizumab was 9 months (IQR: 7-16). There was no overall change in serum alkaline phosphatase level with vedolizumab therapy (median 268 [IQR: 105-551] IU/L at baseline versus 249 [IQR: 183-634] IU/L, P = 0.99 at week 30). No significant changes in other liver biochemistries or the Mayo PSC Risk Score were demonstrated at week 30. Clinical remission was achieved at week 30 in 55% of Crohn's disease and 29% of ulcerative colitis patients. Seven (21%) patients ceased vedolizumab; six patients stopped therapy due to persistent IBD activity and one for worsening of liver biochemistries. CONCLUSION: Vedolizumab treatment in patients with PSC and IBD did not improve liver biochemistry but was associated with improvement in bowel disease and a favourable safety profile.
BACKGROUND: Blocking of lymphocyte trafficking to bile ducts is a potential mechanism to alter the disease course of patients with primary sclerosing cholangitis (PSC). AIM: To describe the effect of the α4 β7 integrin antibody, vedolizumab, on liver biochemistry and disease activity in patients with PSC and inflammatory bowel disease (IBD). METHODS: This is a retrospective multi-centre study of adult patients with a diagnosis of both IBD and PSC. The primary outcome was change in serum alkaline phosphatase level at weeks 14 and 30. Secondary outcomes included changes in other liver biochemistries and in clinical outcomes for the bowel disease. A safety analysis for adverse events was performed. RESULTS: Thirty-four patients (16 Crohn's disease, 18 ulcerative colitis) were included. Nine (26%) had a history of liver transplant. Median follow-up on vedolizumab was 9 months (IQR: 7-16). There was no overall change in serum alkaline phosphatase level with vedolizumab therapy (median 268 [IQR: 105-551] IU/L at baseline versus 249 [IQR: 183-634] IU/L, P = 0.99 at week 30). No significant changes in other liver biochemistries or the MayoPSC Risk Score were demonstrated at week 30. Clinical remission was achieved at week 30 in 55% of Crohn's disease and 29% of ulcerative colitispatients. Seven (21%) patients ceased vedolizumab; six patients stopped therapy due to persistent IBD activity and one for worsening of liver biochemistries. CONCLUSION:Vedolizumab treatment in patients with PSC and IBD did not improve liver biochemistry but was associated with improvement in bowel disease and a favourable safety profile.
Authors: Emily E Vivio; Navya Kanuri; Joanna J Gilbertsen; Kelly Monroe; Neelendu Dey; Chien-Huan Chen; Alexandra M Gutierrez; Matthew A Ciorba Journal: J Crohns Colitis Date: 2015-12-17 Impact factor: 9.071
Authors: K J Hillan; K E Hagler; R N MacSween; A M Ryan; M E Renz; H H Chiu; R K Ferrier; G L Bird; A P Dhillon; L D Ferrell; S Fong Journal: Liver Date: 1999-12
Authors: Brian G Feagan; Paul Rutgeerts; Bruce E Sands; Stephen Hanauer; Jean-Frédéric Colombel; William J Sandborn; Gert Van Assche; Jeffrey Axler; Hyo-Jong Kim; Silvio Danese; Irving Fox; Catherine Milch; Serap Sankoh; Tim Wyant; Jing Xu; Asit Parikh Journal: N Engl J Med Date: 2013-08-22 Impact factor: 91.245
Authors: Matthew Rutter; Brian Saunders; Kay Wilkinson; Steve Rumbles; Gillian Schofield; Michael Kamm; Christopher Williams; Ashley Price; Ian Talbot; Alastair Forbes Journal: Gastroenterology Date: 2004-02 Impact factor: 22.682
Authors: Keith D Lindor; Kris V Kowdley; Velimir A C Luketic; M Edwyn Harrison; Timothy McCashland; Alex S Befeler; Denise Harnois; Roberta Jorgensen; Jan Petz; Jill Keach; Jody Mooney; Carol Sargeant; Julie Braaten; Tamara Bernard; Debra King; Ellen Miceli; Jeff Schmoll; Tanya Hoskin; Prabin Thapa; Felicity Enders Journal: Hepatology Date: 2009-09 Impact factor: 17.425
Authors: Bertus Eksteen; Allister J Grant; Alice Miles; Stuart M Curbishley; Patricia F Lalor; Stefan G Hübscher; Michael Briskin; Mike Salmon; David H Adams Journal: J Exp Med Date: 2004-11-22 Impact factor: 14.307
Authors: Marco Spadaccini; Alessio Aghemo; Flavio Caprioli; Ana Lleo; Federica Invernizzi; Silvio Danese; Maria F Donato Journal: United European Gastroenterol J Date: 2019-06-20 Impact factor: 4.623
Authors: Sebastian Zundler; Claudia Günther; Andreas E Kremer; Mario M Zaiss; Veit Rothhammer; Markus F Neurath Journal: Nat Rev Gastroenterol Hepatol Date: 2022-08-09 Impact factor: 73.082